|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-2-1
|
|
pubmed:abstractText |
Bortezomib and Lenalidomide have been shown to be effective in the control of multiple myeloma (MM) progression. We have investigated their role in the in vitro expression of Osterix by primary osteoblast cultures from MM patients and found that Osterix RNA was constitutively down-regulated in these cells. Treatment of osteoblasts with Bortezomib resulted in an increase of Osterix RNA and in enhanced activity of both BMP-2 and Runx2. Instead, Lenalidomide was unable to modify Osterix transcription. These findings provide additional evidence suggesting that, at least in vitro, Bortezomib promotes the osteoblast maturation whereas Lenalidomide is ineffective.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/BMP2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Morphogenetic Protein 2,
http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Core Binding Factor Alpha 1 Subunit,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RUNX2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Sp7 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Thalidomide,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/bortezomib,
http://linkedlifedata.com/resource/pubmed/chemical/lenalidomide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2009 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
243-9
|
|
pubmed:dateRevised |
2010-4-23
|
|
pubmed:meshHeading |
pubmed-meshheading:19656567-Antineoplastic Agents,
pubmed-meshheading:19656567-Bone Morphogenetic Protein 2,
pubmed-meshheading:19656567-Boronic Acids,
pubmed-meshheading:19656567-Case-Control Studies,
pubmed-meshheading:19656567-Cell Differentiation,
pubmed-meshheading:19656567-Core Binding Factor Alpha 1 Subunit,
pubmed-meshheading:19656567-Down-Regulation,
pubmed-meshheading:19656567-Humans,
pubmed-meshheading:19656567-Multiple Myeloma,
pubmed-meshheading:19656567-Osteoblasts,
pubmed-meshheading:19656567-Pyrazines,
pubmed-meshheading:19656567-RNA, Messenger,
pubmed-meshheading:19656567-Thalidomide,
pubmed-meshheading:19656567-Transcription Factors,
pubmed-meshheading:19656567-Tumor Cells, Cultured
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
|
|
pubmed:affiliation |
DIMO, Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza Giulio Cesare 11, 70124, Bari, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
